Livzon Pharmaceutical Group (000513) Fundamentals 2026 — P/E 13.9x, Revenue Analysis | SniperIQ
Livzon Pharmaceutical Group (000513) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥27.4B, trading at ¥30.90 on the SHZ. This SniperIQ fundamentals page covers Livzon Pharmaceutical Group's valuation (P/E 13.9x, P/B 1.9x), profitability (net margin 16.8%), revenue (¥11.9B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Livzon Pharmaceutical Group's market cap?
Livzon Pharmaceutical Group (000513) has a market capitalization of approximately ¥27.4B, trading at ¥30.90 on the SHZ. Market cap moves with the live share price.
What is Livzon Pharmaceutical Group's P/E ratio?
Livzon Pharmaceutical Group's trailing twelve-month P/E ratio is 13.9x, with a price-to-book (P/B) of 1.9x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Livzon Pharmaceutical Group?
Livzon Pharmaceutical Group runs a net profit margin of 16.8%, a gross margin of 65.7%, and an operating margin of 22.7%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Livzon Pharmaceutical Group generate?
Livzon Pharmaceutical Group reported revenue of ¥11.9B for fiscal year 2025, with net income of ¥2.0B and earnings per share (EPS) of 2.27. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Livzon Pharmaceutical Group pay a dividend?
Livzon Pharmaceutical Group offers a trailing dividend yield of about 4.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Livzon Pharmaceutical Group financially healthy?
Livzon Pharmaceutical Group carries a debt-to-equity ratio of 0.26x and a current ratio of 1.96x, with a market beta of 0.24. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Livzon Pharmaceutical Group a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Livzon Pharmaceutical Group (000513) the key facts are: market cap ¥27.4B, P/E 13.9x, revenue ¥11.9B, 52-week range 27.67-44.37. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Livzon Pharmaceutical Group's full fundamentals live
Get Livzon Pharmaceutical Group's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.